Author(s)

Navid Larson

Affiliation(s)

Ohio State University, John Glenn School of Public Affairs, Columbus, OH, United States.

Corresponding Author

Navid Larson

ABSTRACT

Regenerative medicine is based on the structure and function of tissues to repair and treat affected areas. A discipline that damages tissues and organs. The emergence and development of regenerative medicine provides new ideas for the treatment of diseases and alleviates the shortage of transplanted tissues and organs. The problem. The process of tissue and organ regeneration is very complex and requires stable environment. Stable cytokine expression is a key factor in tissue and organ regeneration, and gene therapy can effectively solve this problem. Gene therapy The seed cells of the therapy can stably and continuously secrete the cytokines required for regeneration, provide a stable local environment, and improve the efficiency of tissue repair. therefore, Gene therapy will produce more ideal results in the field of regenerative medicine Treatment Effect.

KEYWORDS

Gene therapy; Regenerative medicine; Tissue repair

CITE THIS PAPER

Navid Larson. Application progress of gene therapy in the field of regenerative medicine. World Journal of Biomedical Sciences. 2023, 1(2): 16-19. DOI:10.61784/wjbs231239.

REFERENCES

[1]  Kaufmann KB, Buning H, Galy A, et al. EMBO molecular medicine, 2013, 5(11): 1642-1661.

[2] Kimelman Bleich  N, Kallai  I, Lieberman JR, et  al. Gene therapy ap- proaches to regenerating  bone. Advanced  drug  delivery  reviews, 2012, 64(12): 1320-1330.

[3] Thybo KH, Eskesen V. The most important reason for lack of organ do- nation is  family  refusal. Danish  medical  journal, 2013, 60(2): A4585.

[4] Jarvinen TA, May U, Prince S. Systemically Administered, Target  Or- gan-Specific Therapies  for  Regenerative  Medicine. International journal of molecular sciences, 2015, 16(10): 23556-23571.

[5]  Southwood LL, Kawcak CE, Hidaka C, et al. Evaluation of direct in vi- vo gene transfer in an equine metacarpal IV ostectomy model using an  adenoviral vector encoding the bone morphogenetic protein-2 and protein-7 gene. Veterinary surgery, 2012, 41(3): 345-354.

[6]  Ishihara  A, Zekas  LJ, Litsky  AS, et al. Dermal fibroblast-mediated  BMP2  therapy to accelerate bone healing in an equine osteotomy model. Journal of orthopaedic research, 2010, 28(3): 403-411.

[7]  Rakoczy EP, Narfstrom K. Gene therapy for eye as regenerative medi- cine? Lessons from RPE65 gene therapy for Leber’s Congenital Amau- rosis. The international journal of biochemistry & cell biology, 2014(56): 153-157.

[8]  Cisternas P, Henriquez JP, Brandan E, et al. Wnt signaling in skeletal muscle dynamics: myogenesis, neuromuscular synapse and fibrosis.Molecular neurobiology, 2014, 49(1): 574-589.

[9]  Evans CH, Huard J. Gene therapy approaches to regenerating the mus- culoskeletal system. Nat Rev Rheumatol, 2015, 11(4): 234-242.

[10] Han Xiangzhen, He Huiyu, Hu Yang, etc. human bone morphogenetic protein -2 Recombinant lentiviral vector Transfection of sheep bone marrow mesenchymal stem cells and their osteogenic regulatory effects.  Chinese Journal of Practical Diagnosis and Treatment, 2014, 28(6): 540-542.

[11]  Ishihara  A, Zekas  LJ, Litsky AS, et al. Dermal fibroblast-mediated BMP2  therapy  to  accelerate bone healing  in  an  equine  osteotomy model. Journal of orthopaedic research: official publication of the Orthopaedic Research Society, 2010, 28(3): 403-411.

[12]  Rincon MY, VandenDriessche T, Chuah MK. Gene therapy for cardio- vascular disease: advances  in  vector  development, targeting, and  de- livery for clinical translation. Cardiovascular research, 2015, 108(1): 4-20.

[13]  Olea FD, De Lorenzi A, Cortes C, et al. Combined VEGF gene trans- fer and erythropoietin in ovine reperfused myocardial infarction.International journal of cardiology, 2013, 165(2): 291-298.

[14]  Xue  XD, Liu  Y, Zhang J, et al. Bcl-xL Genetic Modification En- hanced the Therapeutic Efficacy  of Mesenchymal  Stem  Cell  Trans- plantation in the Treatment of Heart Infarction. Stem cells international, 2015(2015): 176409. doi: 10. 1155/2015/176409.

[15]  Kantor  B, McCown T, Leone P, et al. Clinical applications involving CNS gene transfer. Advances in genetics, 2014(87): 71-124.

[16]  Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-term evalu- ation of a phase 1 study of AADC gene therapy for Parkinson’s dis- ease. Human Gene Therapy, 2012, 23(4): 377-381.

[17]  LeWitt  PA, Rezai  AR, Leehey  MA, et  al. AAV2-GAD  gene therapy  for advanced Parkinson’s disease: a double-blind, sham-surgery con- trolled, randomised trial. Lancet  Neurology, 2011, 10(4): 309-319.

[18] Wells A, Nuschke A, Yates CC. Skin tissue repair: Matrix micro environmental influences. Matrix  Biology, 2015. doi: 10.1016/j.matbio.2015.08.001.

[19]  Di  WL, Larcher  F, Semenova  E, et  al. Ex-vivo gene  therapy  restores  LEKTI activity  and  corrects the  architecture  of Netherton  syndrome- derived skin grafts. Molecular therapy: the journal of the American  Society of Gene Therapy, 2011, 19(2):408-416.